Hydroxyamine

Hydroxyamine

SCHEMBL5894189

CCCCCS(=O)(=O)N1CCNCC1C(=O)O.NO

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 2/20 0.40
MMP8 P22894 2/20 0.37
MMP3 P08254 2/20 0.37
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
MMP1 P03956 2/20 0.33
MMP9 P14780 2/20 0.33
MMP13 P45452 2/20 0.33
MMP7 P09237 1/20 0.33
GNAI3 P08754 4/20 0.33
GNAO1 P09471 4/20 0.33
GNAI1 P63096 4/20 0.33
ITGB3 P05106 1/20 0.32
ITGA2B P08514 1/20 0.32
ADAM17 P78536 1/20 0.31
SMYD3 Q9H7B4 2/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroxyamine SCHEMBL5894442 0.80 FKBP1A (0.50) FKBP1AMMP8MMP3ALDH1A1MMP1
SCHEMBL10815653 0.79 FKBP1A (0.48) FKBP1AMMP8MMP3ALDH1A1MAPT
SCHEMBL3256301 0.77 FKBP1A (0.56) FKBP1AMMP8MMP3ALDH1A1MMP1
SCHEMBL3256303 0.77 FKBP1A (0.56) FKBP1AMMP8MMP3ALDH1A1MMP1
SCHEMBL5195643 0.77 MMP8 (0.35) FKBP1AMMP8MMP3ALDH1A1MAPT
SCHEMBL6830973 0.76 FKBP1A (0.58) FKBP1AMMP8MMP3MMP1MMP13
SCHEMBL6830972 0.76 FKBP1A (0.58) FKBP1AMMP8MMP3MMP1MMP13
SCHEMBL6667249 0.76 MMP13 (0.51) FKBP1AMMP8MMP3MMP1MMP9
Hydroxyamine SCHEMBL6529639 0.76 FKBP1A (0.41) FKBP1AMMP8MMP3MMP1MMP13
SCHEMBL6831371 0.75 FKBP1A (0.54) FKBP1AMMP8MMP3ALDH1A1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030242-B2 Selective inhibition of aggrecanase in osteoarthritis treatment PFIZER INC (US) 2006-04-18 US disclosed
US-20050227997-A1 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction NOE MARK C 2005-10-13 US disclosed
EP-1081137-A1 Selective inhibitors of aggrecanase in osteoarthritis treatment Pfizer Products Inc. (US) 2001-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227997-A1 1-[4-(2-methyl-benzyloxy)-benzenesulfonyl]-4-aminoacetyl-3-methyl-piperazine-2-carboxylic acid hydroxyamide; potent enzyme inhibitor of metalloproteinases, for treating joint disease, prevent cartilage destruction MMP3, MMP1, MMP13 FKBP1A 2344/4885MMP8 28/4885MMP3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.